The lawsuits against drugmakers and distributors have opened up the potential for billions of dollars in liabilities as governments grapple with mounting human and financial costs of the opioid epidemic. (Photo: Shutterstock)
Oxycontin-maker Purdue Pharma LP is preparing for a possible bankruptcy filing as it faces hundreds of lawsuits over its role in the U.S. opioid epidemic, Reuters and the Wall Street Journal reported Monday.
The drugmaker has hired advisers to prepare for a potential filing, the Journal said, citing people familiar with the matter. Bankruptcy would let the company negotiate claims with some of the more than 1,500 cities, states, local governments and other entities that have sued Purdue and other health companies over their roles in the opioid epidemic.
Purdue spokesman Robert Josephson declined to comment on the reports.
“We are, however, committed to ensuring that our business remains strong and sustainable,” Josephson said in an email. “We have ample liquidity and remain committed to meeting our obligations to the patients who benefit from our medicines, our suppliers and other business partners.”
The lawsuits against drugmakers and distributors have opened up the potential for billions of dollars in liabilities as governments grapple with mounting human and financial costs of the opioid epidemic.
More than 700,000 people in the U.S. died from drug overdoses from 1999 to 2017, according to the Centers for Disease Control and Prevention, and more than two-thirds of those were opioid-related. While the epidemic of addiction and death began with prescription pills marketed by Purdue and other drug companies, it has shifted to include heroin and synthetic compounds like fentanyl.
Purdue and other drugmakers have said they didn't act improperly in marketing their medicines.
Shares of other companies named in the lawsuits fell after the reports. Drugmaker Endo International Plc was down as much as 15 percent, and Mallinckrodt Plc fell as much as 6.7 percent. Drug distributors AmerisourceBergen Corp., Cardinal Health Corp. and McKesson Corp. also fell.
Read more about the fall of Purdue Pharma:
- New lawsuit unveils scope of Purdue's 'extraordinary efforts' to push opioids
- Purdue brings in “Turnaround Kid” to overhaul image
- New Jersey joins states suing Purdue Pharma for opioid marketing
Copyright 2019 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
